Completed PHASE1 INTERVENTIONAL 6-arm NCT03972280

Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis

A Multicenter, Open-label, 2-regimen, Repeat-dose Study to Assess the Safety and Pharmacokinetics of Intravenous CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis

Sponsor: CSL Behring

Conditions Hidradenitis Suppurativa Palmoplantar Pustulosis

Interventions Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody

Updated 21 times since 2019 Last updated: May 25, 2023 Started: Jul 4, 2019 Primary completion: Oct 4, 2022 Completion: Oct 4, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Hidradenitis Suppurativa and Palmoplantar Pustulosis, this trial is completed. The trial is conducted by CSL Behring and has accumulated 21 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

21 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jun 2023 — Jul 2024 [monthly]

Completed PHASE1
Nov 2022 — Jun 2023 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Sep 2022 — Nov 2022 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting

▶ Show 16 earlier versions

Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE1
May 2022 — Jul 2022 [monthly]

Recruiting PHASE1
Apr 2022 — May 2022 [monthly]

Recruiting PHASE1
Jan 2022 — Apr 2022 [monthly]

Recruiting PHASE1
Oct 2021 — Jan 2022 [monthly]

Recruiting PHASE1
Sep 2021 — Oct 2021 [monthly]

Recruiting PHASE1
Jun 2021 — Sep 2021 [monthly]

Recruiting PHASE1
Mar 2021 — Jun 2021 [monthly]

Recruiting PHASE1
Feb 2021 — Mar 2021 [monthly]

Recruiting PHASE1
Jan 2021 — Feb 2021 [monthly]

Recruiting PHASE1
Aug 2020 — Jan 2021 [monthly]

Recruiting PHASE1

Status: Active Not Recruiting → Recruiting
May 2020 — Aug 2020 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Feb 2020 — May 2020 [monthly]

Recruiting PHASE1
Sep 2019 — Feb 2020 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Aug 2019 — Sep 2019 [monthly]

Not Yet Recruiting PHASE1
Jul 2019 — Aug 2019 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CSL Behring

Data source: CSL Behring

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Berlin, Germany , Bochum, Germany , Copenhagen, Denmark , Darlinghurst, Australia , Darmstadt, Germany , Dresden, Germany , Fremantle, Australia , Hellerup, Denmark , Parkville, Australia , Roskilde, Denmark and 1 more location